Literature DB >> 31396704

Bound, free, and total L-dopa measurement in plasma of Parkinson's disease patients.

Thomas Müller1, Hans Michael Thiede2.   

Abstract

Peaks and troughs of levodopa in plasma contribute to pulsatile postsynaptic dopamine receptor stimulation in patients with Parkinson's disease. Measurement of levodopa plasma levels mostly only considers the total levodopa plasma concentration. Objectives were to determine bound, free, and total plasma levodopa and to investigate their correlations to each other. We employed reversed-phase high-performance liquid chromatography combined with electrochemical detection. Bound levodopa was computed as difference between total and free L-dopa values. Close correlations between free and total (R = 0.93, p < 0.0001), bound and total (R = 0.91, p < 0.0001) plasma levodopa appeared. A considerable variability of levodopa concentrations occurred. The ratio between bound and free levodopa did not differ in patients with a higher and lower oral daily levodopa dosing. Free, bound, and total levodopa plasma levels are closely related. Estimation of the total levodopa level only seems to be meaningful.

Entities:  

Keywords:  Levodopa; Parkinson’s disease; Plasma concentrations

Mesh:

Substances:

Year:  2019        PMID: 31396704     DOI: 10.1007/s00702-019-02057-1

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  21 in total

Review 1.  Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease.

Authors:  Dag Nyholm
Journal:  Expert Rev Neurother       Date:  2006-10       Impact factor: 4.618

2.  Simultaneous determination of levodopa, carbidopa, entacapone, tolcapone, 3-O-methyldopa and dopamine in human plasma by an HPLC-MS/MS method.

Authors:  Rômulo Pereira Ribeiro; João Cleverson Gasparetto; Raquel de Oliveira Vilhena; Thais Martins Guimarães de Francisco; Thais Martins Guimarães de Francisco; Cleverson Antônio Ferreira Martins; Marco André Cardoso; Roberto Pontarolo; Katherine Athayde Teixeira de Carvalho
Journal:  Bioanalysis       Date:  2015       Impact factor: 2.681

3.  Chronic administration does not alter the accumulation of L-dopa into muscle.

Authors:  S Rose; P Jenner; C D Marsden
Journal:  Mov Disord       Date:  1994-03       Impact factor: 10.338

4.  Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease.

Authors:  T Müller; C Erdmann; S Muhlack; D Bremen; H Przuntek; O Goetze; D Woitalla
Journal:  J Neural Transm (Vienna)       Date:  2006-04-11       Impact factor: 3.575

5.  Optimization of the hydrolysis of conjugated L-DOPA, dopamine and dihydroxyphenylacetic acid in human urine for assay by high-performance liquid chromatography with electrochemical detection.

Authors:  P Tuomainen; P T Männistö
Journal:  Eur J Clin Chem Clin Biochem       Date:  1997-03

Review 6.  Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.

Authors:  Thomas Müller
Journal:  Clin Neuropharmacol       Date:  2013 May-Jun       Impact factor: 1.592

7.  Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease.

Authors:  G Arabia; M Zappia; D Bosco; L Crescibene; A Bagalà; L Bastone; M Caracciolo; M Scornaienghi; A Quattrone
Journal:  Neurol Sci       Date:  2002-09       Impact factor: 3.307

8.  Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease.

Authors:  Siegfried Muhlack; Dirk Woitalla; Jacob Welnic; Svenja Twiehaus; Horst Przuntek; Thomas Müller
Journal:  Neurosci Lett       Date:  2004-06-17       Impact factor: 3.046

9.  Binding studies of L-3,4-dihydroxyphenylalanine with human serum albumin.

Authors:  Daniel Pushparaju Yeggoni; Rajagopal Subramanyam
Journal:  Mol Biosyst       Date:  2014-09-11

10.  Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson's disease.

Authors:  Sebastiaan P van Kessel; Alexandra K Frye; Ahmed O El-Gendy; Maria Castejon; Ali Keshavarzian; Gertjan van Dijk; Sahar El Aidy
Journal:  Nat Commun       Date:  2019-01-18       Impact factor: 14.919

View more
  2 in total

1.  Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients.

Authors:  Thomas Müller; Eugen Schlegel; Stephanie Zingler; Hans Michael Thiede
Journal:  Cells       Date:  2022-04-30       Impact factor: 7.666

2.  Wearable Electrochemical Sensors in Parkinson's Disease.

Authors:  Francesco Asci; Giorgio Vivacqua; Alessandro Zampogna; Valentina D'Onofrio; Adolfo Mazzeo; Antonio Suppa
Journal:  Sensors (Basel)       Date:  2022-01-26       Impact factor: 3.576

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.